These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents? Ridker PM Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469 [No Abstract] [Full Text] [Related]
24. The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits. Spartalis M; Siasos G; Mastrogeorgiou M; Spartalis E; Kaminiotis VV; Mylonas KS; Kapelouzou A; Kontogiannis C; Doulamis IP; Toutouzas K; Nikiteas N; Iliopoulos DC Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7765-7776. PubMed ID: 34982438 [TBL] [Abstract][Full Text] [Related]
25. Genetic and Epigenetic Regulation of the Innate Immune Response to Gout. de Lima JD; de Paula AGP; Yuasa BS; de Souza Smanioto CC; da Cruz Silva MC; Dos Santos PI; Prado KB; Winter Boldt AB; Braga TT Immunol Invest; 2023 Apr; 52(3):364-397. PubMed ID: 36745138 [TBL] [Abstract][Full Text] [Related]
26. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Ridker PM; Rane M Circ Res; 2021 May; 128(11):1728-1746. PubMed ID: 33998272 [TBL] [Abstract][Full Text] [Related]
33. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Ridker PM; MacFadyen JG; Thuren T; Libby P Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417 [TBL] [Abstract][Full Text] [Related]
34. Anti-atherosclerosis of oligomeric proanthocyanidins from Rhodiola rosea on rat model via hypolipemic, antioxidant, anti-inflammatory activities together with regulation of endothelial function. Zhou Q; Han X; Li R; Zhao W; Bai B; Yan C; Dong X Phytomedicine; 2018 Dec; 51():171-180. PubMed ID: 30466614 [TBL] [Abstract][Full Text] [Related]
35. The Role of Colchicine in Acute Coronary Syndromes. Vaidya K; Martínez G; Patel S Clin Ther; 2019 Jan; 41(1):11-20. PubMed ID: 30185392 [TBL] [Abstract][Full Text] [Related]
36. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. Cronstein BN; Sunkureddi P J Clin Rheumatol; 2013 Jan; 19(1):19-29. PubMed ID: 23319019 [TBL] [Abstract][Full Text] [Related]
37. The Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE): protocol for a randomised, double-blind, placebo-controlled trial. Boczar KE; Shin S; deKemp RA; Dowlatshahi D; Tavoosi A; Wiefels C; Liu P; Lochnan H; MacPherson PA; Chong AY; Torres C; Leung E; Tawakol A; Ahmadi A; Garrard L; Lefebvre C; Kelly C; MacPhee P; Tilokee E; Raggi P; Wells GA; Beanlands R BMJ Open; 2023 Nov; 13(11):e074463. PubMed ID: 37949621 [TBL] [Abstract][Full Text] [Related]
38. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ; Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077 [TBL] [Abstract][Full Text] [Related]